While seviteronel is both a CYP17 and AR inhibitor, CYP17 is not commonly expressed in breast cancer cell lines, and the culture media used has supplemented cholesterol and steroid hormones, thus preventing cells from relying on CYP17 for androgen production. The gene discussed is CYP17A1; the disease is breast carcinoma.